BRAF and non-small cell lung carcinoma: These driver alterations have successfully guided the development of novel targeted therapies for subsets of patients with NSCLC and EGFR mutations, as well as ALK or ROS translocations, and now a variety of other small subsets (BRAF mutations, HER2 mutations, etc).